PSNL
Personalis Inc
NASDAQ · Life Sciences Tools & Services
$8.06
+0.64 (+8.63%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 126.82M | 127.25M | 811.88M | 842.44M | 788.11M |
| Net Income | -121,830,686 | -110,021,691 | 59.99M | 62.65M | 45.28M |
| EPS | — | — | — | — | — |
| Profit Margin | -96.1% | -91.3% | 7.4% | 7.4% | 5.8% |
| Rev Growth | -0.3% | -0.3% | -1.0% | +3.3% | +14.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 3.08M | 3.08M | 102.68M | 109.54M | 111.95M |
| Total Equity | 354.57M | 354.57M | 428.61M | 454.92M | 451.32M |
| D/E Ratio | 0.01 | 0.01 | 0.24 | 0.24 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -113,625,164 | -108,312,167 | 96.00M | 87.86M | 84.18M |
| Free Cash Flow | — | — | 40.11M | 62.43M | 43.12M |